Search results
... Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis...
Benzinga· 18 hours agoThe KOL event, "Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring...
ASLAN expands research on atopic dermatitis treatment By Investing.com
Investing.com· 6 days agoASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 22 hours agoQ: Regarding the atopic dermatitis study, are you including patients who have previously had dupilumab and failed? A: (Richard Miller, CEO) The trial includes patients who ...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks via Yahoo Finance· 6 days agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 5 days agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
Stopping the sniffles: Don't let nasal polyps steal your scent-sibility
La Crosse Tribune· 4 days ago“Nasal polyps are soft, noncancerous growths on the nasal passages or sinus linings that can cause...
Earnings call: Kymera Therapeutics reports progress in drug development By Investing.com
Investing.com· 5 days agoKymera Therapeutics, during their first quarter 2024 earnings call, provided a comprehensive update...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 6 days agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first